Comparative Pharmacology
Head-to-head clinical analysis: IDVYNSO versus ZYTIGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IDVYNSO versus ZYTIGA.
IDVYNSO vs ZYTIGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IDVYNSO is a selective dopamine D3 receptor antagonist, which modulates dopaminergic neurotransmission in the mesolimbic pathway.
Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor that selectively inhibits the enzyme CYP17 (17α-hydroxylase/C17,20-lyase). This inhibition blocks androgen production in the testes, adrenal glands, and prostate tumor tissue.
5 mg/kg IV once daily for 14 days; then 2.5 mg/kg IV once daily for 14 days.
1000 mg orally once daily on an empty stomach, at least 1 hour before or 2 hours after a meal, in combination with prednisone 5 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is 12–18 hours, supporting twice-daily dosing in patients with normal renal function.
The terminal elimination half-life of abiraterone is approximately 12 hours (range 9–18 hours) following oral administration, supporting twice-daily dosing.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%, with the remainder metabolized.
Abiraterone is primarily eliminated via hepatic metabolism with less than 1% excreted unchanged in urine. Approximately 88% of a radiolabeled dose is recovered in feces (mainly as metabolites) and about 5% in urine.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent